Clinical Application of Inhaled Cicl esonide and Enoxaparin for COVID- 19 Pneumonia

Request Full Text  

Price

$42.00

Article Title

Clinical Application of Inhaled Cicl esonide and Enoxaparin for COVID- 19 Pneumonia

Publication

International Journal of Gerontology

ISSN

1873-958X

Volume

16

Issue

2

Year

2022

Pages

144-146

Authors

Kuan-Chih Kuo

Data Format

PDF

Abstract

The novel coronavirus disease 2019 (COVID-19) pandemic is a threat to global public health. The disease
is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and characterized
by high transmission, high mortality, lack of effective treatment, and prolonged hospitalization. Currently,
there is no clear management strategy for COVID-19 infection. Some clinical evidence suggests
that the use of inhaled ciclesonide and enoxaparin subcutaneous injection maybe helpful for disease
treatment. In this article, we report the successful treatment of a 65-year-old male with COVID-19
pneumonia with Inhaled corticosteroid and enoxaparin subcutaneously, which also shortened the
course of the disease without significant complications.

Keywords

COVID-19, pneumonia, ciclesonide, inhaled corticosteroid, enoxaparin

Subject Fields

Pneumonia

References

1. Taiwan Centers for Disease Control. Cumulative COVID-19 cases and
deaths worldwide. Available at https://sites.google.com/cdc.gov.tw/
2019-ncov/. Accessed March 20, 2021.
2. Liu Y, Gayle AA, Wilder-Smith A, et al. The reproductive number of
COVID-19 is higher compared to SARS coronavirus. J TravelMed. 2020;
27(2):taaa021.
...

Request Full Text